Clinical Trials | April 30, 2026
Pfizer drug delivers breakthrough in late-stage blood cancer trial
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The agreement could rise to $900 million if key commercial milestones are met
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Subscribe To Our Newsletter & Stay Updated
